<doc>
  <docmeta id="113hr2186ih">
    <bill congress="113" type="hr" number="2186" version="ih"/>
    <revision size="41870" annotations="0" status="complete" id="5" commit-time="2013-08-20T22:13:31Z" committer="mbohmer" doc="113hr2186ih/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H635DDF9B14B74ABA8F36FA1831C29138" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 2186 IH: Verifying Authority and Legality In Drug Compounding Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-05-23</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2186</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130523">May 23, 2013</action-date>
			<action-desc>
        <sponsor name-id="M000133">Mr. Markey</sponsor> (for
			 himself, <cosponsor name-id="S000480">Ms. Slaughter</cosponsor>,
			 <cosponsor name-id="C001049">Mr. Clay</cosponsor>, and
			 <cosponsor name-id="R000053">Mr. Rangel</cosponsor>) introduced the following
			 bill; which was referred to the <committee-name committee-id="HIF00">Committee
			 on Energy and Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to
		  provide for the compounding of drug products.</official-title>
	</form>
	<legis-body id="H8FB3AEC48CB849899076651C274C23E5" style="OLC">
		<section id="HD8754CD0AA014B91B21E7DCE8526FE01" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Verifying Authority and Legality In
			 Drug Compounding Act of 2013</short-title>
        </quote> or the <quote>
          <short-title>VALID Compounding Act</short-title>
        </quote>.</text>
		</section>
    <section id="HA3406042AF55492E89F1E2F0818BA8A6">
      <enum>2.</enum>
      <header>Application of
			 Federal law to practice of pharmacy compounding</header>
			<subsection id="H74071B3430A9418D90BE2C07DBD12396">
        <enum>(a)</enum>
        <header>Amendment</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A">Section 503A of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">
              <cato:entity-ref entity-type="uscode" value="usc/21/353a">21 U.S.C. 353a</cato:entity-ref>
            </external-xref>)</cato:entity> is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="H9466012D143C4D9388A3DEA05BC6D6E9" style="OLC">
					<section id="H7852A4545A844F6FB6D42EFE4EFC428B">
            <enum>503A.</enum>
            <header>Pharmacy
				compounding</header>
						<subsection id="HDF435FE89C7A4E158AF0ED134247DDB3">
              <enum>(a)</enum>
              <header>In
				general</header>
              <text display-inline="yes-display-inline">
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:501/ss:a/p:2/sp:B">Sections
				501(a)(2)(B)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">502(f)(1)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505</cato:entity-ref> shall not apply with respect to a drug product
				if each of the following applies:</text>
							<paragraph id="H629B81D5CF684EC4A6FFC0F57E383B72">
                <enum>(1)</enum>
                <text>Except as provided
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d" proposed="true">subsection (d)</cato:entity-ref>, the drug product is compounded for an identified individual
				patient based on the receipt of a prescription order.</text>
							</paragraph>
              <paragraph id="HB3288A14D88F41498D6C67AC65DE308C">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">The drug product is compounded by a
				licensed pharmacist in a State-licensed pharmacy or a Federal facility, or by a
				licensed physician, pursuant to such prescription order or notation.</text>
							</paragraph>
              <paragraph id="H12A0485E80CD48929269166EE123A849">
                <enum>(3)</enum>
                <text display-inline="yes-display-inline">In the case of a drug product that is
				compounded using bulk substances (as defined in section 207.3(a)(4) of title
				21, Code of Federal Regulations (or any successor regulations)—</text>
								<subparagraph id="H87D7DB7BD8EC4FEFB104DEA4137075CC">
                  <enum>(A)</enum>
                  <text>such bulk
				substances—</text>
									<clause id="H04ECF60E504141439E614FF1AC316F1B">
                    <enum>(i)</enum>
                    <text>are components of
				one or more drugs for which an approval of an application filed under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">subsection (b)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">(j) of section 505</cato:entity-ref> is in effect;</text>
									</clause>
                  <clause id="HE9BA4299FF4F401DB3648D2192DEDDBC">
                    <enum>(ii)</enum>
                    <text>are components of
				drugs that may be lawfully marketed in the United States without such an
				approval pursuant to the definition of a new drug in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:201">section 201</cato:entity-ref>; or</text>
									</clause>
                  <clause id="HF2E2549F97074C8A913C44BB6B45B84F">
                    <enum>(iii)</enum>
                    <text>appear on the
				list in effect under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b" proposed="true">subsection (b)</cato:entity-ref>; and</text>
									</clause>
                </subparagraph>
                <subparagraph id="HE798B0ED23914DCA9A4630CC044CB2E9">
                  <enum>(B)</enum>
                  <text>such bulk
				substances comply with the standards of an applicable United States
				Pharmacopeia or National Formulary monograph, if a monograph exists.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H7F2F6529684F4B8D8A4D2978621C93A0">
                <enum>(4)</enum>
                <text>Any bulk substance
				used for purposes of compounding the drug product—</text>
								<subparagraph id="HE255287372E74F25B70832008F4DCC3F">
                  <enum>(A)</enum>
                  <text>is manufactured by
				an establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> (including a foreign
				establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:i">section 510(i)</cato:entity-ref>); and</text>
								</subparagraph>
                <subparagraph id="HA986FFF123E84BD49094099160131095">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">is accompanied by valid certificates of
				analysis.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H5D1A5C893AFA4671BD8397EC859B42F1">
                <enum>(5)</enum>
                <text>The pharmacist or
				physician compounding the drug product complies with the standards of any
				applicable United States Pharmacopeia chapters on pharmacy compounding.</text>
							</paragraph>
              <paragraph id="H38D71588B78E46DFBF0B200A23E538DF">
                <enum>(6)</enum>
                <text display-inline="yes-display-inline">The drug product, including the dosage form
				and any ingredient thereof—</text>
								<subparagraph id="H62DF1AF1D9994999A53CF67932144309">
                  <enum>(A)</enum>
                  <text>is not included in
				the list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c" proposed="true">subsection (c)</cato:entity-ref>; and</text>
								</subparagraph>
                <subparagraph id="H5336224DF00647FFB621F94CB8933868">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">is not withdrawn or removed from the market
				because such drug product or any ingredient thereof has been found to be unsafe
				or not effective.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H48F94B5362154BCC9D0CBAD3AEB85A4B">
                <enum>(7)</enum>
                <text>Subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e" proposed="true">subsection (e)</cato:entity-ref>, the drug product is not a copy of a commercially available
				drug.</text>
							</paragraph>
              <paragraph id="HEFDEA6BFDE304C74A73A2ECB452396E3">
                <enum>(8)</enum>
                <text display-inline="yes-display-inline">If the drug product is produced using
				high-risk sterile compounding, the drug product is compounded in accordance
				with the standards, processes, and procedures established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:f" proposed="true">subsection
				(f)</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
            <subsection id="H1B75AD4F5BD4439799C5C7E31F2DF005">
              <enum>(b)</enum>
              <header>List of bulk
				substances from which drug products may be compounded</header>
							<paragraph id="HED1106095F944F56A7EA443AFBA633D4">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:iii" proposed="true">subsection (a)(3)(A)(iii)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall, by guidance—</text>
								<subparagraph id="H946BD3EB727E4FAE9D3A72413A61E1E8">
                  <enum>(A)</enum>
                  <text>develop and
				maintain a list of bulk substances from which drug products may be compounded;
				and</text>
								</subparagraph>
                <subparagraph id="HA8DCF5894713468EB8D90A4CC131837F">
                  <enum>(B)</enum>
                  <text>include in the
				list only bulk substances that are not described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:ii" proposed="true">(ii) of
				subsection (a)(3)(A)</cato:entity-ref> and may be compounded to meet a medical need that cannot
				be filled by using a bulk substance that is described in such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:ii" proposed="true">(ii)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H5D392E8ED3734AF6957E317E7AD2CB35">
                  <enum>(C)</enum>
                  <text>specify for each
				bulk substance on the list under this subsection any limitation on compounding
				the bulk substance; and</text>
								</subparagraph>
                <subparagraph id="H58B696A29315482B8981E8BE92BED5EE">
                  <enum>(D)</enum>
                  <text>specify for each
				bulk substance on the list under this subsection the particular medical need
				that is met by placing such substance on the list.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="HBD960ABB0E354A07874C90E463F171A0">
                <enum>(2)</enum>
                <header>Initial
				publication; updates</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<subparagraph id="H972F1075CF5A472E8EFB158F972B3B69">
                  <enum>(A)</enum>
                  <text>not later than 1
				year after the date of the enactment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013" proposed="true">
                      <short-title>Verifying Authority and Legality In Drug Compounding Act
				of 2013</short-title>
                    </cato:entity-ref>, publish an initial list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>; and</text>
								</subparagraph>
                <subparagraph id="HAD6E8948C8214F4EA4D9D3CDAA582BD4">
                  <enum>(B)</enum>
                  <text>not less
				frequently than every year thereafter, review and, as appropriate, update the
				list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H09887EE57C334408A09268AB7A120E9A">
                <enum>(3)</enum>
                <header>Availability</header>
                <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref> available on the public Web
				site of the Food and Drug Administration.</text>
							</paragraph>
              <paragraph id="HFF34B6A9B669418CA292239B90DDA4D4">
                <enum>(4)</enum>
                <header>Transmission to
				State regulatory agencies</header>
                <text display-inline="yes-display-inline">Upon publication of the initial list under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref>, and upon each update to the list, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall transmit
				an up-to-date copy of the list to the agency in each State with primary
				responsibility for regulating pharmacies.</text>
							</paragraph>
              <paragraph id="H58640BF2287A4DF68AA6054FFE7B6ED4">
                <enum>(5)</enum>
                <header>Petitions</header>
								<subparagraph id="HB831EA6B1033400593C5610822C3598F">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>In carrying out this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				receive and consider petitions from any person identifying a substance that
				should be added to, or removed from, the list under this subsection.</text>
								</subparagraph>
                <subparagraph id="HA7DC6C44C54E45FCABA8AA8E14FD72E2">
                  <enum>(B)</enum>
                  <header>Requirement for
				petitions seeking to add a bulk substance</header>
                  <text>Any petition seeking to
				add a bulk substance to the list under this subsection shall specify the
				reasons—</text>
									<clause id="H69096BE5FA3F4C92A53444FFDB936B5C">
                    <enum>(i)</enum>
                    <text>why the bulk
				substance is needed for a procedure or population; and</text>
									</clause>
                  <clause id="H5F5F8F809EA744DC9848978295672193">
                    <enum>(ii)</enum>
                    <text>why such need is
				not met by bulk substances that are described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:ii" proposed="true">(ii) of
				subsection (a)(3)(A)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H356C7AF6ECC641089C70547913A82BE9">
                  <enum>(C)</enum>
                  <header>Approval or
				denial</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall approve or deny any petition received
				under this paragraph, and update the list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref> accordingly, not
				later than 90 days after receipt of the petition, unless an extension of time
				is mutually agreed upon by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and the petitioner.</text>
								</subparagraph>
                <subparagraph id="H48DC3864A0D346F2A131A707FADA8726">
                  <enum>(D)</enum>
                  <header>Final agency
				action</header>
                  <text display-inline="yes-display-inline">A decision of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> to approve or deny a petition received under this paragraph shall
				constitute final agency action subject to judicial review.</text>
								</subparagraph>
                <subparagraph id="HF993A35793A24EBBAC63D41FBD5EF3E0">
                  <enum>(E)</enum>
                  <header>Public
				posting</header>
                  <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				publically post—</text>
									<clause id="H4BBDD2A8F8E047E492F9F26C394A28A9">
                    <enum>(i)</enum>
                    <text>all petitions
				received under this paragraph within 21 days of receipt; and</text>
									</clause>
                  <clause display-inline="no-display-inline" id="H0CBB9BD5042F4941895D795500CDE0ED">
                    <enum>(ii)</enum>
                    <text>each approval,
				denial, and extension under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:5/sp:C" proposed="true">subparagraph (C)</cato:entity-ref> promptly.</text>
									</clause>
                </subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HB0B6472A865949749A1DCF892A0F6F16">
              <enum>(c)</enum>
              <header>List of drug
				products that should not be compounded</header>
							<paragraph id="H5AC13D570E50408992B905A440D0DB13">
                <enum>(1)</enum>
                <header>In
				general</header>
                <text>For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:6" proposed="true">subsection (a)(6)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall,
				by guidance—</text>
								<subparagraph id="H19129E0D06FE42708DA9505409A0BC26">
                  <enum>(A)</enum>
                  <text>develop and
				maintain a list of drug products that should not be compounded, including any
				categories, dosage forms, or ingredients of such drug products; and</text>
								</subparagraph>
                <subparagraph id="H718F57ABFD3B416FA953C8146E19ADC6">
                  <enum>(B)</enum>
                  <text>include on such
				list, at a minimum—</text>
									<clause id="HF7296C42004A4069AF9EB149E5E1E4BB">
                    <enum>(i)</enum>
                    <text display-inline="yes-display-inline">drug products (or categories, dosage forms,
				or ingredients thereof) whose compounding is reasonably likely to cause an
				adverse effect on safety or effectiveness of such drug product, including
				extended release products, metered dose inhalers, transdermal patches, and
				liposomal products; and</text>
									</clause>
                  <clause id="H5EDC472B78B6467E8B4680CC394453C5">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">drug products (or categories, dosage forms,
				or ingredients thereof) that have been withdrawn or removed from the market
				because they have been found to be unsafe or not effective.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph id="H9FA25F531E3440E19F5B885BAC54F950">
                <enum>(2)</enum>
                <header>Applicability of
				certain provisions</header>
                <text>The provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:2" proposed="true">paragraphs (2)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:3" proposed="true">(3)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:4" proposed="true">(4)
				of subsection (b)</cato:entity-ref> shall apply with respect to the list under this subsection to
				the same extent and in the same manner as such provisions apply with respect to
				the list under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b" proposed="true">subsection (b)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H0FBC00B972944E4AB6F9C9E108F823C3">
                <enum>(3)</enum>
                <header>Petitions</header>
                <text display-inline="yes-display-inline">In carrying out this subsection, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall receive and consider petitions from any person identifying a
				drug product that should be added to, or removed from, the list under this
				subsection. <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:2/sp:C..E" proposed="true">Subparagraphs (C) through (E) of subsection (b)(2)</cato:entity-ref> shall apply with
				respect to petitions under this paragraph to the same extent and in the same
				manner as such subparagraphs apply with respect to petitions under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:5" proposed="true">subsection
				(b)(5)</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
            <subsection commented="no" id="H413E41838014483F8E0273E90609C6A9">
              <enum>(d)</enum>
              <header>Exception to
				requirement of identified individual patient</header>
							<paragraph commented="no" id="H36C6A309708F46EBA5DF34D2A0A83BC7">
                <enum>(1)</enum>
                <header>In
				General</header>
                <text>A pharmacy or pharmacist that is not required to be
				registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> may compound a drug product without regard to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref> if the pharmacy or pharmacist—</text>
								<subparagraph commented="no" id="HFD8C181137C3406C9C17E63DA0DF9856">
                  <enum>(A)</enum>
                  <text>registers with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> as specified pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2" proposed="true">paragraph (2)</cato:entity-ref>; and</text>
								</subparagraph>
                <subparagraph commented="no" id="HA324B7D9E9C347C3A4B45A649CDCB763">
                  <enum>(B)</enum>
                  <text>agrees to comply
				with any condition of operation or limitation of activity specified by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, including the conditions and limitations specified pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2" proposed="true">paragraph (2)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="H086B86B436084B60929BD945DC6D446C">
                <enum>(2)</enum>
                <header>Registration and
				requirements</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify by regulation for each
				type of pharmacy or pharmacist compounding drug products pursuant to the
				exception under this subsection—</text>
								<subparagraph commented="no" id="H8657164175DB4C04B0409A7EA117604B">
                  <enum>(A)</enum>
                  <text>the registration
				requirements for such pharmacy or pharmacist and the information that must be
				submitted with the registration, which information shall include—</text>
									<clause commented="no" id="H3CCE731ADA0D4DAA899BC4FEA81A22D4">
                    <enum>(i)</enum>
                    <text>the name and
				location of the pharmacy;</text>
									</clause>
                  <clause commented="no" id="H90CC614B697E4AF7A7E93500A99813DC">
                    <enum>(ii)</enum>
                    <text>the types of
				drugs that are compounded;</text>
									</clause>
                  <clause commented="no" id="HBE163F712C7A42FB935F6B7D361E45B6">
                    <enum>(iii)</enum>
                    <text>the active
				ingredients in each such drug;</text>
									</clause>
                  <clause commented="no" id="HB0FCEB276FEE46F0989290E881FF44FE">
                    <enum>(iv)</enum>
                    <text>the source and
				strength of the active ingredient in each drug;</text>
									</clause>
                  <clause commented="no" id="H3EEC3B02822742C0BE4858B15BD0831C">
                    <enum>(v)</enum>
                    <text>the dosage form
				and route of administration of each drug;</text>
									</clause>
                  <clause commented="no" id="H4E490FE071A748E58F98DA1360E4A610">
                    <enum>(vi)</enum>
                    <text>the number of
				individual units produced of each drug;</text>
									</clause>
                  <clause commented="no" id="H170C739056E94B6797567D490C13A0AB">
                    <enum>(vii)</enum>
                    <text display-inline="yes-display-inline">the States to which drugs were
				shipped;</text>
									</clause>
                  <clause id="HB5750850C1934BDD8D5CD21F8566DFEC">
                    <enum>(viii)</enum>
                    <text>the number of
				individual units of each drug that are shipped to each State; and</text>
									</clause>
                  <clause commented="no" id="H9E68C45F8F28498B9AFBC3DF43D63E73">
                    <enum>(ix)</enum>
                    <text>affirmation that
				the pharmacy or pharmacist is in compliance with State pharmacy licensing
				regulations;</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="HDA8FA7FD4E19446A9BCA061E49B7D944">
                  <enum>(B)</enum>
                  <text>the frequency in
				which information described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> must be submitted;</text>
								</subparagraph>
                <subparagraph commented="no" id="HD869031868134F638D400B707E2FD227">
                  <enum>(C)</enum>
                  <text>the conditions of
				operation, including good manufacturing practices and requirements for
				third-party testing, applicable to the compounding of drugs; and</text>
								</subparagraph>
                <subparagraph commented="no" id="H3F166A3C6B694F5C9790A43E1B15D368">
                  <enum>(D)</enum>
                  <text>any limitations on
				the activities of such pharmacy or pharmacist.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="H77F4727DE31F4B2BA26C948263AB0C51">
                <enum>(3)</enum>
                <header>Types of
				pharmacies eligible</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify separate
				requirements for each type of pharmacy and pharmacist authorized to compound
				drug products pursuant to the exception under this subsection. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall include separate requirements for—</text>
								<subparagraph commented="no" id="H07B3F2F97E7D4EFCBD06AB735A410C2D">
                  <enum>(A)</enum>
                  <text>any pharmacy or
				pharmacist within a hospital system that is compounding drug products
				exclusively for dispensing to patients within that hospital system; and</text>
								</subparagraph>
                <subparagraph commented="no" id="H89F3CE26C984449EA815D68B2007ACEB">
                  <enum>(B)</enum>
                  <text>any pharmacy or
				pharmacist that compounds sterile drug products.</text>
								</subparagraph>
              </paragraph>
              <paragraph commented="no" id="HC85F1F6969D94033A9E4F931916B4A37">
                <enum>(4)</enum>
                <header>Memorandum of
				understanding</header>
								<subparagraph commented="no" id="HCE0520396C6648B6B8009A6F96A06A9C">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text display-inline="yes-display-inline">Subject to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may enter into appropriate memoranda of
				understanding with States to address State implementation of the exception
				under this subsection—</text>
									<clause commented="no" id="HA69BDD50F49E47FDB7642BCA2B819D56">
                    <enum>(i)</enum>
                    <text>ensuring, to the
				Secretary’s satisfaction, that the State will implement the exception under
				this subsection in accordance with the requirements of this section; and</text>
									</clause>
                  <clause commented="no" id="H6595D78C298C42DDA44ED842F6F3715A">
                    <enum>(ii)</enum>
                    <text>including such
				other information and assurances as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may require.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="HD3C986F494554F27992DDA7B3CFA0C8D">
                  <enum>(B)</enum>
                  <header>Process;
				criteria</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
									<clause commented="no" id="H5D172DC8D0BB49CA83DA47CCAD2C339E">
                    <enum>(i)</enum>
                    <text>establish a
				process and criteria for entering into a memorandum of understanding under this
				paragraph, including the sharing of information between State and Federal
				authorities; and</text>
									</clause>
                  <clause commented="no" id="HC7A414C28E4F47DDB0550760BD025358">
                    <enum>(ii)</enum>
                    <text display-inline="yes-display-inline">reevaluate each such memorandum of
				understanding not less than every 5 years to ensure, to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>’s
				satisfaction, that the State’s implementation of the memorandum of
				understanding continues to conform to the requirements of this section.</text>
									</clause>
                </subparagraph>
                <subparagraph commented="no" id="H0AE8E6F63C6E4B20BC1FABF899F7C833">
                  <enum>(C)</enum>
                  <header>Exclusive
				Federal authority</header>
                  <text display-inline="yes-display-inline">The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall retain exclusive Federal authority to implement the exception
				under this subsection with respect to pharmacies and pharmacists that—</text>
									<clause commented="no" id="HB961CDADB08546C98DC8DC4E2F336C73">
                    <enum>(i)</enum>
                    <text>perform high-risk
				sterile compounding; or</text>
									</clause>
                  <clause commented="no" id="H482571654C2A444BB2BC11A03CC9D6BE">
                    <enum>(ii)</enum>
                    <text>compound drug
				products for shipment across State lines.</text>
									</clause>
                </subparagraph>
              </paragraph>
              <paragraph commented="no" id="H9414B6D680114EC79F02ADD1D4127560">
                <enum>(5)</enum>
                <header>Maintenance of
				list</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall maintain a publically available
				list—</text>
								<subparagraph id="H73027F8793834A00A400F6F73D1D2955">
                  <enum>(A)</enum>
                  <text>identifying all
				pharmacies and pharmacists registered under this subsection; and</text>
								</subparagraph>
                <subparagraph id="H2D33B59B56B643F1B72E8587B5773089">
                  <enum>(B)</enum>
                  <text>indicating, for
				each such pharmacy and pharmacist, whether the pharmacy or pharmacist is
				subject to regulation by a State pursuant to a memorandum of understanding in
				effect under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="H709BC58FF26D458C8081BF44217C47C7">
              <enum>(e)</enum>
              <header>Exceptions
				regarding copies of commercially available drugs</header>
              <text>A drug that is a
				copy of a commercially available drug may be compounded pursuant to this
				section without regard to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:7" proposed="true">subsection (a)(7)</cato:entity-ref> if—</text>
							<paragraph commented="no" id="H9167F5B9D64541BE86C30A3325B8E751">
                <enum>(1)</enum>
                <subparagraph commented="no" display-inline="yes-display-inline" id="H778B1495695E42ECB39B332B03ED2983">
                  <enum>(A)</enum>
                  <text>the commercially
				available drug that is being compounded is at the time of distribution on the
				drug shortage list under section 506E, and the pharmacy has provided notice to
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> that such drug is being compounded not later than 5 days after
				distributing such drug; or</text>
								</subparagraph>
                <subparagraph id="H9D140E0D318E4C738BB2868BBE29D3AC" indent="up1">
                  <enum>(B)</enum>
                  <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines that com­pound­ing
				the drug product is necessary to protect public health or wellbeing; and</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H7809257C270444A5ACCC0D82986068F3">
                <enum>(2)</enum>
                <text>in the case of a
				commercially available drug marketed pursuant to a risk evaluation and
				mitigation strategy approved under section 505–1 and including one or more
				elements to assure safe use, the pharmacy or pharmacist compounding the drug
				that is a copy of such commercially available drug demonstrates to the
				Secretary that controls will be used that are comparable to such elements to
				assure safe use.</text>
							</paragraph>
            </subsection>
            <subsection id="HA905B2E5339347008996D4C8FD2ECCF5">
              <enum>(f)</enum>
              <header>High-Risk
				sterile compounding</header>
              <text display-inline="yes-display-inline">For
				purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:8" proposed="true">subsection (a)(8)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish standards,
				processes, and procedures for high-risk sterile compounding.</text>
						</subsection>
            <subsection id="H7192D002B4B54B359FA8A1F9EFE72D2A">
              <enum>(g)</enum>
              <header>Inspections</header>
              <text display-inline="yes-display-inline">Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a/p:2/sp:A">section 704(a)(2)(A)</cato:entity-ref>, the
				facilities of any pharmacy or pharmacist compounding drug products under this
				section—</text>
							<paragraph id="H55CEB438B61747E290A002E9BD53FA26">
                <enum>(1)</enum>
                <text>shall be subject
				to inspection under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref>; and</text>
							</paragraph>
              <paragraph id="HCC8FF35969AC4E2E9600F4ABDE2CB1EF">
                <enum>(2)</enum>
                <text>shall, upon
				request of an officer or employee designated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, permit such
				officer or employee at all reasonable times to have access to, and to copy and
				verify, records for purposes of determining compliance with the provisions of
				this Act applicable to such compounding.</text>
							</paragraph>
            </subsection>
            <subsection id="HA7F050E2832748CEBC80C17D099BFCB2">
              <enum>(h)</enum>
              <header>Sharing of
				information</header>
              <text display-inline="yes-display-inline">If during an
				inspection of the facilities of a pharmacy or pharmacist under this section the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> discovers a violation of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall give notice of
				the violation—</text>
							<paragraph id="HDA446A08D4D54788AE9B2D2D3C5BAF37">
                <enum>(1)</enum>
                <text>to the State in
				which the facilities are located; and</text>
							</paragraph>
              <paragraph id="HEBA18B2EB8B94B3599D856E5168B1BC1">
                <enum>(2)</enum>
                <text>to any State to
				which the pharmacy or pharmacist has shipped a drug product during the
				preceding 30 days.</text>
							</paragraph>
            </subsection>
            <subsection id="H9E9042C087B947179B13E0B9B176D5A7">
              <enum>(i)</enum>
              <header>Labeling</header>
              <text display-inline="yes-display-inline">The labeling of any drug product compounded
				pursuant to this section shall include—</text>
							<paragraph id="H1799716F441B4559841E13A32559C16D">
                <enum>(1)</enum>
                <text display-inline="yes-display-inline">the name of each drug and ingredient
				included;</text>
							</paragraph>
              <paragraph id="H3F152C16F76A45DEA0A38C9D39BD985C">
                <enum>(2)</enum>
                <text>the name, address,
				and phone number of the licensed compounding pharmacy, pharmacist, or
				physician;</text>
							</paragraph>
              <paragraph id="H2F807AF742394872AB23E0671DEBB009">
                <enum>(3)</enum>
                <text>the date on which
				the drug was compounded;</text>
							</paragraph>
              <paragraph id="H58583D7D6F5546E2998ABCB8DC720F54">
                <enum>(4)</enum>
                <text>instructions for
				storage and use;</text>
							</paragraph>
              <paragraph id="H43E4D91AE1C14956966955F495326FE3">
                <enum>(5)</enum>
                <text>the following
				statement: <quote>This drug has not been tested for safety and effectiveness
				and is not approved by the FDA. This drug was made specifically for you because
				your health care provider determined that no FDA-approved product would suit
				your needs. Serious adverse reactions to this drug should be reported to the
				FDA at ________________, to the pharmacy where the drug was received, and to
				your health care provider.</quote> (The blank shall specify a phone number and
				a Web site, to be provided by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for purposes of this subsection.);
				and</text>
							</paragraph>
              <paragraph id="H36E3B904E4E5441BAC400638A918B608">
                <enum>(6)</enum>
                <text>such other
				information as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may require.</text>
							</paragraph>
            </subsection>
            <subsection id="HC9BFE751985C4AE088799B0A7671A15A">
              <enum>(j)</enum>
              <header>Reporting by
				pharmacists and physicians</header>
							<paragraph id="H4848CF31F02D42D589820340A12E7ADB">
                <enum>(1)</enum>
                <header>Adverse
				event</header>
                <text>If a pharmacist or physician compounding a drug product
				pursuant to this section becomes aware of any adverse event associated with the
				use of such product, not later than 10 calendar days after becoming so aware,
				the pharmacist or physician shall report such adverse event to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
							</paragraph>
              <paragraph commented="no" id="HA78DDD09217447C9B4B82686D774D817">
                <enum>(2)</enum>
                <header>Information
				related to risk of injury or death</header>
                <text display-inline="yes-display-inline">If a pharmacist or physician compounding a
				drug product pursuant to this section becomes aware of information concerning
				any bacteriological, fungal, or other contamination; any significant chemical,
				physical, or other change; or any deterioration of a compounded drug product
				that has already been distributed by the pharmacist or physician, that could
				cause serious injury or death, not later than 2 calendar days after becoming so
				aware, the pharmacist or physician shall report such information to the
				Secretary.</text>
							</paragraph>
            </subsection>
            <subsection id="HC9BBBF37E15D4EC6849554D9DCC42F3C">
              <enum>(k)</enum>
              <header>Compounding
				establishment and reinspection fees</header>
							<paragraph id="HFB2CBAFDA145432CB55D6A48D995C62B">
                <enum>(1)</enum>
                <header>Definitions</header>
                <text>In
				this subsection—</text>
								<subparagraph id="H0E388FD248E143E38CDF0A688313F056">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">the term <term>affiliate</term> has the
				meaning given such term in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section 735(11)</cato:entity-ref>;</text>
								</subparagraph>
                <subparagraph id="H5BD3FA4855954B0F8B275EB73E22A293">
                  <enum>(B)</enum>
                  <text>the term
				<term>covered compounding pharmacy</term> means a pharmacy that, pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d" proposed="true">subsection (d)</cato:entity-ref> (the exception to the requirement of an identified individual
				patient)—</text>
									<clause id="H7EA5C55E7F234F32B956B6123C8550C3">
                    <enum>(i)</enum>
                    <text>performs high-risk
				sterile compounding;</text>
									</clause>
                  <clause id="HB4F3AFE9EB414229B032219C65A52F24">
                    <enum>(ii)</enum>
                    <text>compounds drug
				products for shipment across State lines; or</text>
									</clause>
                  <clause id="H8AFBADBE14AF40EF9071D47AD8785983">
                    <enum>(iii)</enum>
                    <text>otherwise
				performs compounding pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d" proposed="true">subsection (d)</cato:entity-ref> that is not regulated by a
				State pursuant to a memorandum of understanding under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d/p:4" proposed="true">subsection (d)(4)</cato:entity-ref>;</text>
									</clause>
                </subparagraph>
                <subparagraph id="H6E0CC1D6181A427794B26FBF09EAE9F3">
                  <enum>(C)</enum>
                  <text>the term
				<term>gross annual sales</term> means the total worldwide gross annual sales,
				in United States dollars, for a covered com­pound­ing pharmacy, including the
				sales of all the affiliates of the covered compounding pharmacy; and</text>
								</subparagraph>
                <subparagraph id="H384F996E17034175BE577120B50FC7CD">
                  <enum>(D)</enum>
                  <text>the term
				<term>reinspection</term> means, with respect to a covered compounding
				pharmacy, one or more inspections conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref> subsequent to an
				inspection conducted under such provision which identified noncompliance
				materially related to an applicable requirement of this Act, specifically to
				determine whether compliance has been achieved to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>’s
				satisfaction.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H14A56F8BB9E94D5498DC7103264549DD">
                <enum>(2)</enum>
                <header>Establishment
				and reinspection fees</header>
								<subparagraph id="H543E9BBC8BB24C58B702E06F66AFBBD1">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>For fiscal year 2015 and each subsequent fiscal year, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, in accordance with this subsection, assess and collect—</text>
									<clause id="H9FDC821FBCBE4695A169C009C9C153E9">
                    <enum>(i)</enum>
                    <text>an
				annual establishment fee from each covered compounding pharmacy; and</text>
									</clause>
                  <clause id="H3AAC409EFCD94F62BE1C878DCDFD4543">
                    <enum>(ii)</enum>
                    <text>a
				reinspection fee from each covered compounding pharmacy subject to a
				reinspection in such fiscal year.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H49FD3212F3DC4D6FB931DF4A25928EBC">
                  <enum>(B)</enum>
                  <header>Multiple
				reinspections</header>
                  <text>A covered compounding pharmacy subject to multiple
				reinspections in a fiscal year shall be subject to a reinspection fee for each
				reinspection.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H6D6F7813F94B414782F6B55D38DBE02B">
                <enum>(3)</enum>
                <header>Establishment
				and reinspection fee setting</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish the
				establishment and reinspection fee to be collected under this subsection for
				each fiscal year, based on the methodology described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4" proposed="true">paragraph (4)</cato:entity-ref> and shall
				publish such fee in a Federal Register notice not later than 60 days before the
				start of each such year.</text>
							</paragraph>
              <paragraph id="H85B7B549461D4F9F9DACDC553786998A">
                <enum>(4)</enum>
                <header>Amount of
				establishment fee and reinspection fee</header>
								<subparagraph id="H60D2CC03270445F1942556E02C8D0E8D">
                  <enum>(A)</enum>
                  <header>In
				general</header>
                  <text>For each covered compounding pharmacy in a fiscal
				year—</text>
									<clause id="H9221A02893734841BA66B99C1144747B">
                    <enum>(i)</enum>
                    <text>except as provided
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>, the amount of the annual establishment fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:2" proposed="true">paragraph
				(2)</cato:entity-ref> shall be equal to the sum of—</text>
										<subclause id="H7B7DB4D2B4BE44F8A81155B78FEFBA28">
                      <enum>(I)</enum>
                      <text>$15,000,
				multiplied by the inflation adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>;
				plus</text>
										</subclause>
                    <subclause id="H5F10E13296024A4AAF99A4B9F119A51A">
                      <enum>(II)</enum>
                      <text>the small
				business adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref>; and</text>
										</subclause>
                  </clause>
                  <clause id="H3110B1D252A44EC58A46E9D5713DA012">
                    <enum>(ii)</enum>
                    <text>the amount of any
				reinspection fee (if applicable) under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:2" proposed="true">paragraph (2)</cato:entity-ref> shall be equal to $15,000,
				multiplied by the inflation adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:B" proposed="true">subparagraph
				(B)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H54DCBC9AE8BB4AD6A08978A173065AB8">
                  <enum>(B)</enum>
                  <header>Inflation
				adjustment factor</header>
									<clause id="HBBF293C876C641D0B674789217E85D84">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>For fiscal year 2015 and subsequent fiscal years, the fee
				amounts established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be adjusted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by
				notice, published in the Federal Register, for a fiscal year by the amount
				equal to the sum of—</text>
										<subclause id="H48E0DD1FCA3B4758BFA27C52B8C5FD44">
                      <enum>(I)</enum>
                      <text>one;</text>
										</subclause>
                    <subclause id="H3420CB4578334596AF940380F1658969">
                      <enum>(II)</enum>
                      <text>the average
				annual percent change in the cost, per full-time equivalent position of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, of all personnel compensation and benefits paid
				with respect to such positions for the first 3 years of the preceding 4 fiscal
				years, multiplied by the proportion of personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal years;
				and</text>
										</subclause>
                    <subclause id="HAE72F26D9EAF452690F7A41321FA3D8B">
                      <enum>(III)</enum>
                      <text>the average
				annual percent change that occurred in the Consumer Price Index for urban
				consumers (U.S. City Average; Not Seasonally Adjusted; All items; Annual Index)
				for the first 3 years of the preceding 4 years of available data multiplied by
				the proportion of all costs other than personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal
				years.</text>
										</subclause>
                  </clause>
                  <clause id="HE7F71419262248E787646695A46C87B8">
                    <enum>(ii)</enum>
                    <header>Compounded
				basis</header>
                    <text>The adjustment made each fiscal year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref> shall
				be added on a compounded basis to the sum of all adjustments made each fiscal
				year after fiscal year 2014 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:B/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H6A5FF5F6A2A94B82B96D518CE560644B">
                  <enum>(C)</enum>
                  <header>Small business
				adjustment factor</header>
                  <text>The small business adjustment factor referred
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:A/cl:i/scl:II" proposed="true">subparagraph (A)(i)(II)</cato:entity-ref> shall be an amount established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for
				each fiscal year based on the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>’s estimate of—</text>
									<clause id="H37B32C7E0D914D77B086A1B2ED4BC7B6">
                    <enum>(i)</enum>
                    <text>the number of
				small businesses that will pay a reduced establishment fee for such fiscal
				year; and</text>
									</clause>
                  <clause id="HE5D15D933BE94AD7B2A18664EFB05B13">
                    <enum>(ii)</enum>
                    <text>the adjustment to
				the establishment fee necessary to achieve total fees equaling the total fees
				that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> would have collected if no entity qualified for the small
				business exception in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:D" proposed="true">subparagraph (D)</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H0796015473F2442ABF81073BEB142E9A">
                  <enum>(D)</enum>
                  <header>Exception for
				small businesses</header>
									<clause id="HEF52E5501D6E4B398549CF848E579D23">
                    <enum>(i)</enum>
                    <header>In
				general</header>
                    <text>In the case of a covered compounding pharmacy with gross
				annual sales of $1,000,000 or less in the 12 months ending April 1 of the
				fiscal year immediately preceding the fiscal year in which the fees under this
				subsection are assessed, the amount of the establishment fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:2" proposed="true">paragraph
				(2)</cato:entity-ref> for a fiscal year shall be equal to <fraction>1/3</fraction> of the amount
				calculated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:A/cl:i/scl:I" proposed="true">subparagraph (A)(i)(I)</cato:entity-ref> in such fiscal year.</text>
									</clause>
                  <clause id="H7F52B10C4D1941CC810F6A708CB92245">
                    <enum>(ii)</enum>
                    <header>Application</header>
                    <text>To
				qualify for the exception under this subparagraph, a small business shall
				submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such exception, in a format
				specified by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in guidance, certifying its gross annual sales for
				the 12 months ending April 1 of the fiscal year immediately preceding the
				fiscal year in which fees under this subsection are assessed. Any such
				application must be submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than April 30 for the
				following fiscal year. Any statement or representation made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall be subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1001">
                        <external-xref legal-doc="usc" parsable-cite="usc/18/1001">section 1001</external-xref> of title 18, United States Code</cato:entity-ref>.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H61078909DC5C4F9E9097B913C3AA868E">
                  <enum>(E)</enum>
                  <header>Crediting of
				fees</header>
                  <text>In establishing the small business adjustment factor under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:4/sp:C" proposed="true">subparagraph (C)</cato:entity-ref> for a fiscal year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall provide for the
				crediting of fees from the previous year to the next year if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				overestimated the amount of the small business adjustment factor for such
				previous fiscal year, and consider the need to account for any adjustment of
				fees and such other factors as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines appropriate.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H879561991DF34786A862ED5C094CD723">
                <enum>(5)</enum>
                <header>Use of
				fees</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make all of the fees collected pursuant
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:2/sp:A/cl:i" proposed="true">clauses (i)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:2/sp:A/cl:ii" proposed="true">(ii) of paragraph (2)(A)</cato:entity-ref> available solely to pay for the
				costs of oversight of covered compounding pharmacies.</text>
							</paragraph>
              <paragraph id="HC79706F205D94B4B99EC4847E84B5FB5">
                <enum>(6)</enum>
                <header>Supplement not
				supplant</header>
                <text>Funds received by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> pursuant to this
				subsection shall be used to supplement and not supplant any other Federal funds
				available to carry out the activities described in this section.</text>
							</paragraph>
              <paragraph id="H0646FFA79C7C45E59BE3278516EB2763">
                <enum>(7)</enum>
                <header>Crediting and
				availability of fees</header>
                <text>Fees authorized under this subsection shall
				be collected and available for obligation only to the extent and in the amount
				provided in advance in appropriations Acts. Such fees are authorized to remain
				available until expended. Such sums as may be necessary may be transferred from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> salaries and expenses appropriation account
				without fiscal year limitation to such appropriation account for salaries and
				expenses with such fiscal year limitation. The sums transferred shall be
				available solely for the purpose of paying the costs of oversight of covered
				compounding pharmacies.</text>
							</paragraph>
              <paragraph id="HFA576B7DEF83453590A3D8EA8DA09104">
                <enum>(8)</enum>
                <header>Collection of
				fees</header>
								<subparagraph id="H963522C08A204917B7A395D9C55F0647">
                  <enum>(A)</enum>
                  <header>Establishment
				fee</header>
                  <text>A covered compounding pharmacy shall remit the establishment
				fee due under this subsection in a fiscal year when submitting a registration
				pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d" proposed="true">subsection (d)</cato:entity-ref> for such fiscal year.</text>
								</subparagraph>
                <subparagraph id="H7BCB438E7AED4403BA7CD91CA9D34DBB">
                  <enum>(B)</enum>
                  <header>Reinspection
				fee</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify in the Federal Register notice
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k/p:3" proposed="true">paragraph (3)</cato:entity-ref> the manner in which reinspection fees assessed under
				this subsection shall be collected and the timeline for payment of such fees.
				Such a fee shall be collected after the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has conducted a reinspection
				of the covered compounding pharmacy involved.</text>
								</subparagraph>
                <subparagraph id="HBB68E663F6094740ABB69FC621CFD25A">
                  <enum>(C)</enum>
                  <header>Effect of
				failure to pay fees</header>
									<clause id="H3FB50D57C2CA4FE0B9B9C2886AF27608">
                    <enum>(i)</enum>
                    <header>Registration</header>
                    <text>A
				covered compounding pharmacy shall not be considered registered under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:d" proposed="true">subsection (d)</cato:entity-ref> in a fiscal year until the date that the covered compounding
				pharmacy remits the establishment fee under this subsection for such fiscal
				year.</text>
									</clause>
                  <clause id="H14D1740C349A4EF6BEB07E6F26126E58">
                    <enum>(ii)</enum>
                    <header>Misbranding</header>
                    <text>All
				drugs manufactured, prepared, propagated, compounded, or processed by a covered
				compounding pharmacy for which any establishment fee or reinspection fee has
				not been paid as required by this subsection shall be deemed misbranded under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:cc">section 502(cc)</cato:entity-ref> until the fees owed for such covered compounding pharmacy under
				this subsection have been paid.</text>
									</clause>
                </subparagraph>
                <subparagraph id="H64AD819DB3CD46288CA4495730CBCFD9">
                  <enum>(D)</enum>
                  <header>Collection of
				unpaid fees</header>
                  <text>In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not receive
				payment of a fee assessed under this subsection within 30 days after it is due,
				such fee shall be treated as a claim of the United States Government subject to
				provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States
				Code</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H45B2B3B7E29F4B27ABD5E5E1E7EE2590">
                <enum>(9)</enum>
                <header>Annual report to
				congress</header>
                <text display-inline="yes-display-inline">Not later than 120
				days after each fiscal year in which fees are assessed and collected under this
				subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and
				Commerce of the House of Representatives</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health,
				Education, Labor, and Pensions of the Senate</cato:entity-ref>, to include a description of fees
				assessed and collected for each year, a summary description of entities paying
				the fees, and the number of inspections and reinspections of such entities
				performed each year.</text>
							</paragraph>
              <paragraph id="H7B477386E72B41B6B65CAF4FD12EDF61">
                <enum>(10)</enum>
                <header>Authorization
				of appropriations</header>
                <text>
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">For fiscal year 2015 and each subsequent fiscal
				year, there is authorized to be appropriated <cato:property name="purpose">for fees under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">this subsection</cato:entity-ref>
                    </cato:property> <cato:funds-and-year amount="indefinite" year="2015,..">an
				amount equivalent to the total amount of fees assessed for such fiscal year
				under this subsection</cato:funds-and-year>.</cato:entity>
                </text>
							</paragraph>
            </subsection>
            <subsection id="HE769446CEDF54890AB3BE58C0643387A">
              <enum>(l)</enum>
              <header>Definitions</header>
              <text display-inline="yes-display-inline">In this section:</text>
							<paragraph id="H2F77A7A3173C42BDBBCACF274B84C4A5">
                <enum>(1)</enum>
                <text display-inline="yes-display-inline">The terms <term>compound</term> and
				<term>com­pound­ing</term>—</text>
								<subparagraph id="H7DA74EBF8AB5429E9892E6717BEFC4ED">
                  <enum>(A)</enum>
                  <text>do not include
				mixing, reconstituting, or other such acts that are performed in accordance
				with directions contained in approved labeling provided by the product's
				manufacturer and other manufacturer directions consistent with that labeling;
				and</text>
								</subparagraph>
                <subparagraph id="H13B6DE915B0B483E93D79B8C9FCC970D">
                  <enum>(B)</enum>
                  <text>in the case of a
				radioactive drug (as defined in <external-xref legal-doc="usc" parsable-cite="usc/21/310">section 310.3(n)</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulations)), also do not include a minor
				deviation from such directions with regard to radioactivity, volume, or
				stability, that is made by or under the direct supervision of an
				<term>authorized nuclear pharmacist</term> or a physician who is an
				<term>authorized user</term> (as such terms are defined in section 35.2 of
				title 10, Code of Federal Regulations, (or any successor regulations)).</text>
								</subparagraph>
              </paragraph>
              <paragraph id="H005BC040DFFD42088EDEF0F79CB5139D">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">The term <term>copy of a commercially
				available drug product</term> does not include a drug product in which there is
				a change, made for an identified individual patient, which produces for that
				patient a significant difference, as determined by the prescribing
				practitioner, between the compounded drug and the comparable commercially
				available drug product, provided that in the case of a radioactive drug (as
				defined in <external-xref legal-doc="regulation" parsable-cite="cfr/21/310.3">section 310.3(n)</external-xref> of title 21, Code of Federal Regulations (or any
				successor regulations)), the reasons for the determination by the prescribing
				practitioner have been documented and such documentation is maintained by the
				pharmacy.</text>
							</paragraph>
              <paragraph id="H4981E3B4561E478FB6F10BB2D78AFC79">
                <enum>(3)</enum>
                <text>The term
				<term>high-risk sterile compounding</term> means compounding sterile drug
				products using nonsterile ingredients, nonsterile devices, or nonsterile
				components.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="HDC032BA5214F4FA9A815FAD80D6085E1">
        <enum>(b)</enum>
        <header>Misbranding</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502">Section
			 502 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/352">
              <cato:entity-ref entity-type="uscode" value="usc/21/352">21 U.S.C. 352</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by
			 adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H4D85C871471348C5A48233C7EAE8ABE6" style="OLC">
					<subsection id="H26359F3630FA40B18F9F92CCB8CD5658">
            <enum>(bb)</enum>
            <text display-inline="yes-display-inline">If it is a drug product compounded pursuant
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section 503A</cato:entity-ref> and its labeling does not include the information required by
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:i" proposed="true">section 503A(i)</cato:entity-ref>.</text>
					</subsection>
          <subsection id="HD6DBB52930F347D8826D756F051B60B1">
            <enum>(cc)</enum>
            <text display-inline="yes-display-inline">If it is a drug, and it was manufactured,
				prepared, propagated, compounded, or processed by a compounding manufacturer
				for which fees have not been paid as required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:k" proposed="true">section
				503A(k)</cato:entity-ref>.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="HDAA222905D154970B094877C3105B9BA">
        <enum>(c)</enum>
        <header>Conforming
			 amendment</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a/p:2/sp:A">Section 704(a)(2)(A) of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/374">
              <cato:entity-ref entity-type="uscode" value="usc/21/374/a/2/A">21 U.S.C. 374(a)(2)(A)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by inserting <quote>subject to
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section 503A</cato:entity-ref>,</quote> before <quote>pharmacies which maintain
			 establishments</quote>.</text>
			</subsection>
      <subsection id="HFA21CF1CC1AF48C8B870285A9F923F3D">
        <enum>(d)</enum>
        <header>Regulations</header>
        <text display-inline="yes-display-inline">Not later than 1 year after the date of the
			 enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall promulgate final regulations for
			 carrying out the amendments made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:2/ss:a" proposed="true">subsections (a)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:2/ss:b" proposed="true">(b)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:2/ss:c" proposed="true">(c)</cato:entity-ref>.</text>
			</subsection>
      <subsection id="H8B4E25DCE6964A0087D7335F508E2667">
        <enum>(e)</enum>
        <header>Effective
			 date</header>
        <text display-inline="yes-display-inline">The amendments made by
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:2/ss:a" proposed="true">subsections (a)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:2/ss:b" proposed="true">(b)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:2/ss:c" proposed="true">(c)</cato:entity-ref> shall take effect on the date that is 1 year
			 after the date of the enactment of this Act.</text>
			</subsection>
    </section>
    <section id="H145F8E27D8C44EF4A83DAA54AAEAA562">
      <enum>3.</enum>
      <header>Registration of
			 manufacturers com­pound­ing drug products</header>
			<subsection id="HA2BDB68B50384E9893E3F453788653F3">
        <enum>(a)</enum>
        <header>Registration</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:g">Section 510(g) of the Federal Food, Drug,
			 and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360">
              <cato:entity-ref entity-type="uscode" value="usc/21/360/g">21 U.S.C. 360(g)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the end the
			 following: <quote>With respect to compounding drugs, the exemption in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:g/p:1">paragraph
			 (1)</cato:entity-ref> does not apply with respect to any pharmacy to the extent to which the
			 pharmacy is, in effect, manufacturing such drugs, as determined by the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, taking into consideration the extent to which such pharmacy sells
			 the drugs across State lines, the quantity of the drugs sold, and any other
			 factors determined appropriate by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</quote>.</text>
			</subsection>
      <subsection id="HDE88EA571D08476A9B412250C98709DF">
        <enum>(b)</enum>
        <header>Regulations</header>
        <text>Not
			 later than 1 year after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of
			 Health and Human Services</cato:entity-ref> shall promulgate regulations for carrying out the
			 amendment made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref>.</text>
			</subsection>
      <subsection id="H4D32EEA79ABA463DBC2A592BF8707485">
        <enum>(c)</enum>
        <header>Effective
			 date</header>
        <text>The amendment made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Verifying Authority and Legality In Drug Compounding Act of 2013/s:3/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall take effect on
			 the date that is 1 year after the date of the enactment of this Act.</text>
			</subsection>
    </section>
    <section commented="no" id="H112C5D378530475B923CBB273FC181AD">
      <enum>4.</enum>
      <header>No preemption of
			 additional non-Federal requirements</header>
      <text display-inline="no-display-inline">The requirements of this Act (including the
			 requirements of the amendments made by this Act) do not preempt any non-Federal
			 requirement that is in addition to, and compatible with, such
			 requirements.</text>
		</section>
  </legis-body>
</bill>
</doc>